These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31450065)

  • 1. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors.
    Ma W; Wang Y; Chu D; Yan H
    J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4D-QSAR and MIA-QSAR Studies of Aminobenzimidazole Derivatives as Fourth-generation EGFR Inhibitors.
    Jia X; Wei C; Tian N; Yan H; Wang H
    Med Chem; 2024; 20(2):140-152. PubMed ID: 37957859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
    Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
    J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4D-LQTA-QSAR and docking study on potent Gram-negative specific LpxC inhibitors: a comparison to CoMFA modeling.
    Ghasemi JB; Safavi-Sohi R; Barbosa EG
    Mol Divers; 2012 Feb; 16(1):203-13. PubMed ID: 22127637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Dynamics Guided Receptor Independent 4D QSAR Studies of Substituted Coumarins as Anticancer Agents.
    Patil R; Sawant S
    Curr Comput Aided Drug Des; 2015; 11(1):39-50. PubMed ID: 26081557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one derivatives as Aurora A kinase inhibitors: LQTA-QSAR analysis and detailed systematic validation of the developed model.
    Kanhed AM; Dash RC; Parmar N; Das TK; Giridhar R; Yadav MR
    Mol Divers; 2015 Nov; 19(4):965-74. PubMed ID: 26183841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LQTA-QSAR: a new 4D-QSAR methodology.
    Martins JP; Barbosa EG; Pasqualoto KF; Ferreira MM
    J Chem Inf Model; 2009 Jun; 49(6):1428-36. PubMed ID: 19422246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
    Pery N; Rizvi NB; Shafiq MI
    J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
    Mera WA; Alzihlif M; Taha MO; Khanfar MA
    Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-dimensional structure-activity relationship model to predict HIV-1 integrase strand transfer inhibition using LQTA-QSAR methodology.
    de Melo EB; Ferreira MM
    J Chem Inf Model; 2012 Jul; 52(7):1722-32. PubMed ID: 22657398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors.
    Balasubramanian PK; Balupuri A; Kang HY; Cho SJ
    BMC Syst Biol; 2017 Mar; 11(Suppl 2):6. PubMed ID: 28361711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor.
    Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
    Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors.
    Hu Z; Lin Q; Liu H; Zhao T; Yang B; Tu G
    Mol Divers; 2022 Apr; 26(2):757-768. PubMed ID: 33625673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors.
    Wang J; Ran T; Chen Y; Lu T
    Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CORAL: Monte Carlo based global QSAR modelling of Bruton tyrosine kinase inhibitors using hybrid descriptors.
    Ahmadi S; Lotfi S; Afshari S; Kumar P; Ghasemi E
    SAR QSAR Environ Res; 2021 Dec; 32(12):1013-1031. PubMed ID: 34875951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.